Chémobiologie
Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 1, Janvier 2015
Chémobiologie
Page(s) 98 - 104
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153101019
Publié en ligne 6 février 2015
  1. Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 2013 ; 3 : 217–224. [CrossRef] [PubMed]
  2. Antona D, Baudon C, Freymuth F, et al. La rougeole en France. Med Sci (Paris) 2012 ; 28 : 1003–1007. [CrossRef] [EDP Sciences]
  3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010 ; 375 : 1545–1555. [CrossRef] [PubMed]
  4. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013 ; 11 : 836–848. [CrossRef] [PubMed]
  5. International ASSWGoHIVC, Deeks SG, Autran B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12 : 607–614. [CrossRef] [PubMed]
  6. Pockros PJ. Advances in newly developing therapy for chronic hepatitis C virus infection. Front Med 2014 ; 8 : 166–174. [CrossRef] [PubMed]
  7. Pol S.. Virus de l’hépatite C. 25 ans, la fin de l’histoire ?. Med Sci (Paris) 2013 ; 29 : 998–1003. [CrossRef] [EDP Sciences] [PubMed]
  8. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014 ; 508 : 402–405. [CrossRef] [PubMed]
  9. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol 2011 ; 1 : 563–573. [CrossRef] [PubMed]
  10. Prussia A, Thepchatri P, Snyder JP, Plemper RK. Systematic approaches towards the development of host-directed antiviral therapeutics. Int J Mol Sci 2011 ; 12 : 4027–4052. [CrossRef] [PubMed]
  11. Es-Saad S, Tremblay N, Baril M, Lamarre D. Regulators of innate immunity as novel targets for panviral therapeutics. Curr Opin Virol 2012 ; 2 : 622–628. [CrossRef] [PubMed]
  12. Lucas-Hourani M, Munier-Lehmann H, Helynck O, et al. High-throughput screening for broad-spectrum chemical inhibitors of RNA viruses. J Vis Exp 2014 ; 87 : e51222.
  13. MacMicking JD. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol 2012 ; 12 : 367–382. [CrossRef] [PubMed]
  14. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011 ; 3 : 920–940. [CrossRef] [PubMed]
  15. Lucas-Hourani M, Dauzonne D, Jorda P, et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 2013 ; 9 : e1003678. [CrossRef] [PubMed]
  16. Bedard KM, Wang ML, Proll SC, et al. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J Virol 2012 ; 86 : 7334–7344. [CrossRef] [PubMed]
  17. Tai ZF, Zhang GL, Wang F. Identification of small molecule activators of the janus kinase/signal transducer and activator of transcription pathway using a cell-based screen. Biol Pharm Bull 2012 ; 35 : 65–71. [CrossRef] [PubMed]
  18. Patel DA, Patel AC, Nolan WC, et al. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One 2012 ; 7 : e36594. [CrossRef] [PubMed]
  19. Bonavia A, Franti M, Pusateri Keaney E, et al. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci USA 2011 ; 108 : 6739–6744. [CrossRef]
  20. Wang QY, Bushell S, Qing M, et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 2011 ; 85 : 6548–6556. [CrossRef] [PubMed]
  21. Hoffmann HH, Kunz A, Simon VA, et al. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci USA 2011 ; 108 : 5777–5782. [CrossRef]
  22. Smee DF, Hurst BL, Day CW. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 2012 ; 22 : 263–272. [CrossRef] [PubMed]
  23. Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem 2013 ; 56 : 3148–3167. [CrossRef] [PubMed]
  24. Liu S, Neidhardt EA, Grossman TH, et al. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 2000 ; 8 : 25–33. [CrossRef] [PubMed]
  25. Ortiz-Riano E, Ngo N, Devito S, et al. Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor. J Virol 2014 ; 88 : 878–889. [CrossRef] [PubMed]
  26. Marschall M, Niemann I, Kosulin K, et al. Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis. Antiviral Res 2013 ; 100 : 640–648. [CrossRef] [PubMed]
  27. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening Assays. J Biomol Screen 1999 ; 4 : 67–73. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.